(Q38096425)

28 August 2017

title

Rituximab in the treatment of non-Hodgkin's lymphoma--a critical evaluation of randomized controlled trials (English)

1 reference

randomized controlled trial

28 August 2017

main subject

1 reference

1 reference

Morag Meriel Griffin

1

1 reference

28 August 2017

Nick Morley

series ordinal

2

1 reference

28 August 2017

language of work or name

English

0 references

publication date

1 May 2013

1 reference

Expert Opinion on Biological Therapy

28 August 2017

published in

1 reference

28 August 2017

volume

13

1 reference

28 August 2017

issue

5

1 reference

28 August 2017

page(s)

803-811

1 reference

Rituximab: the first monoclonal antibody approved for the treatment of lymphoma

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786698

The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786698

Rituximab: mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786698

Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786698

Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786698

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786698

Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786698

CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786698

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786698

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786698

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786698

Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786698

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786698

Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786698

Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786698

CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786698

Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786698

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP al

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786698

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786698

Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786698

Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786698

Cost-effectiveness of rituximab as maintenance therapy in patients with follicular non-Hodgkin lymphoma after responding to first-line rituximab plus chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786698

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786698

Rituximab maintenance for the treatment of patients with follicular lymphoma: an updated systematic review and meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786698

Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786698

Rituximab for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786698

Treatment of older patients with mantle-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786698

Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: res

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786698

Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786698

Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 Randomized Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786698

Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2013.786698

10.1517/14712598.2013.786698

21 January 2018

Identifiers

DOI

1 reference

28 August 2017

1 reference